{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:28:44Z","timestamp":1793942924669,"version":"4.8.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004196","name":"Odense University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.radonc.2026.111790","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:11:30Z","timestamp":1790896290000},"page":"111790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Stereotactic MRI-guided adaptive radiation therapy (SMART) for locally advanced pancreatic cancer: A prospective single-center cohort study"],"prefix":"10.1016","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7153-7707","authenticated-orcid":false,"given":"Pia Braagaard","family":"Hartfelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne L.H.","family":"Bisgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde Weisz","family":"Ejlsmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Bahij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6705-1561","authenticated-orcid":false,"given":"Tine","family":"Schytte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7270-7967","authenticated-orcid":false,"given":"Faisal","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2925-0586","authenticated-orcid":false,"given":"Per","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5309-2696","authenticated-orcid":false,"given":"Uffe","family":"Bernchou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.radonc.2026.111790_b0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated projection of US cancer incidence and death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.radonc.2026.111790_b0010","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/s41416-022-01752-3","article-title":"Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2): a population-based study","volume":"126","author":"Cabasag","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2026.111790_b0015","unstructured":"(DPCD), D.P.C.D., Danish Pancreatic Cancer Database (DPCD) annual report 2024\/2025. 2024."},{"issue":"11","key":"10.1016\/j.radonc.2026.111790_b0020","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"issue":"5.5","key":"10.1016\/j.radonc.2026.111790_b0025","first-page":"603","article-title":"NCCN guidelines updates: pancreatic cancer","volume":"17","author":"Tempero","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"10485","key":"10.1016\/j.radonc.2026.111790_b0030","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.radonc.2026.111790_b0035","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"Jama"},{"key":"10.1016\/j.radonc.2026.111790_b0040","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2020.01.015","article-title":"Initial treatment and survival in 4163 Danish patients with pancreatic cancer: a nationwide unselected real-world register study","volume":"129","author":"Rasmussen","year":"2020","journal-title":"Eur J Cancer"},{"issue":"30","key":"10.1016\/j.radonc.2026.111790_b0045","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO-24-01502","article-title":"Benefit of chemoradiotherapy versus chemotherapy after induction therapy for conversion of unresectable into resectable pancreatic cancer: the randomized CONKO-007 trial","volume":"43","author":"Fietkau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.radonc.2026.111790_b0050","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijrobp.2011.09.008","article-title":"Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy","volume":"83","author":"Bjerregaard","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111790_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110347","article-title":"Adaptive MRI-guided stereotactic body radiation therapy for locally advanced pancreatic cancer - A phase II study","volume":"197","author":"Weisz Ejlsmark","year":"2024","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.radonc.2026.111790_b0060","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/SLA.0000000000002753","article-title":"Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection","volume":"270","author":"Gemenetzis","year":"2019","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.radonc.2026.111790_b0065","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1097\/JS9.0000000000003992","article-title":"One- and two-year overall survival following stereotactic body radiotherapy versus conventional radiotherapy for pancreatic cancer: a systematic review and meta-analysis","volume":"112","author":"Yang","year":"2026","journal-title":"Int J Surg"},{"issue":"1","key":"10.1016\/j.radonc.2026.111790_b0070","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.radonc.2004.12.022","article-title":"Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma","volume":"76","author":"Hoyer","year":"2005","journal-title":"Radiotherapy and Oncology"},{"issue":"5","key":"10.1016\/j.radonc.2026.111790_b0075","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clon.2022.02.010","article-title":"UK 2022 consensus on normal tissue dose-volume constraints for oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapy","volume":"34","author":"Diez","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"10","key":"10.1016\/j.radonc.2026.111790_b0080","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1080\/0284186X.2019.1627417","article-title":"First clinical experiences with a high field 1.5 T MR linac","volume":"58","author":"Bertelsen","year":"2019","journal-title":"Acta Oncol"},{"issue":"15","key":"10.1016\/j.radonc.2026.111790_b0085","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17152596","article-title":"Multi-institutional comparison of ablative 5-fraction magnetic resonance-guided online adaptive versus 15\/25-fraction computed tomography-guided moderately hypofractionated offline adapted radiation therapy for locally advanced pancreatic cancer","volume":"17","author":"Chuong","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.radonc.2026.111790_b0090","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.3390\/curroncol30070499","article-title":"Radiotherapy for locally advanced pancreatic adenocarcinoma-a critical review of randomised trials","volume":"30","author":"Ejlsmark","year":"2023","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2026.111790_b0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.semradonc.2023.10.002","article-title":"The use of MR-guided radiation therapy for pancreatic cancer","volume":"34","author":"Daamen","year":"2024","journal-title":"Semin Radiat Oncol"},{"issue":"4","key":"10.1016\/j.radonc.2026.111790_b0100","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ijrobp.2023.05.023","article-title":"A multi-institutional phase 2 trial of ablative 5-fraction stereotactic magnetic resonance-guided on-table adaptive radiation therapy for borderline resectable and locally advanced pancreatic cancer","volume":"117","author":"Parikh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.radonc.2026.111790_b0105","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ijrobp.2025.03.046","article-title":"Quality of life and toxicity in patients with pancreatic ductal adenocarcinoma treated with online adaptive stereotactic magnetic resonance guided radiation therapy","volume":"122","author":"Westerhoff","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111790_b0110","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3389\/fonc.2020.01328","article-title":"The MOMENTUM study: an international registry for the evidence-based introduction of MR-guided adaptive therapy","volume":"10","author":"de Mol van Otterloo","year":"2020","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.radonc.2026.111790_b0115","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1080\/0284186X.2021.1949036","article-title":"Tumour motion analysis from planning to end of treatment course for a large cohort of peripheral lung SBRT targets","volume":"60","author":"Nielsen","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2026.111790_b0120","article-title":"Treatment planning for MR-guided SBRT of pancreatic tumors on a 1.5 T MR-Linac: a global consensus protocol","volume":"47","author":"Grimbergen","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111790_b0125","first-page":"54","article-title":"Adaptive radiotherapy: the Elekta Unity MR-linac concept","volume":"18","author":"Winkel","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"issue":"3","key":"10.1016\/j.radonc.2026.111790_b0130","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.radonc.2017.07.028","article-title":"Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer","volume":"125","author":"Bohoudi","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111790_b0135","article-title":"Balancing dose preservation and treatment efficiency in motion-managed magnetic resonance image-guided radiotherapy of pancreatic cancer","volume":"37","author":"Bernchou","year":"2026","journal-title":"Phys Imaging Radiat Oncol"},{"issue":"2","key":"10.1016\/j.radonc.2026.111790_b0140","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.radonc.2026.111790_b0145","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1016\/j.radonc.2026.111790_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110064","article-title":"Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: a multi-center, open-label phase 2 study","volume":"191","author":"Chuong","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111790_b0155","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221150228","article-title":"Multi-institutional outcomes of patients aged 75 years and older with pancreatic ductal adenocarcinoma treated with 5-fraction ablative stereotactic magnetic resonance image-guided adaptive radiation therapy (A-SMART)","volume":"30","author":"Bryant","year":"2023","journal-title":"Cancer Control"},{"issue":"1","key":"10.1016\/j.radonc.2026.111790_b0160","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010007","article-title":"Stereotactic MR-guided adaptive radiotherapy for pancreatic tumors: updated results of the montpellier prospective registry study","volume":"15","author":"Bordeau","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2026.111790_b0165","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.phro.2022.10.003","article-title":"Stereotactic ablative radiation for pancreatic cancer on a 1.5Telsa magnetic resonance-linac system","volume":"24","author":"Tringale","year":"2022","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111790_b0170","article-title":"Patterns of failure after definitive ablative 5-fraction stereotactic body radiation therapy for inoperable pancreatic ductal adenocarcinoma","author":"Chuong","year":"2026","journal-title":"Int J Radiation Oncol*Biol*Phys"},{"key":"10.1016\/j.radonc.2026.111790_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109869","article-title":"Online adaptive radiotherapy: assessment of planning technique and its impact on longitudinal plan quality robustness in pancreatic cancer","volume":"188","author":"Mittauer","year":"2023","journal-title":"Radiother Oncol"},{"issue":"6","key":"10.1016\/j.radonc.2026.111790_b0180","doi-asserted-by":"crossref","DOI":"10.3390\/cancers18060971","article-title":"Conventionally fractionated radiotherapy (CFRT) versus stereotactic body radiotherapy (SBRT) for locally advanced pancreatic cancer: a systematic review and meta-analysis of comparative studies","volume":"18","author":"Montesi","year":"2026","journal-title":"Cancers (Basel)"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026006304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026006304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:14:56Z","timestamp":1793942096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026006304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":36,"alternative-id":["S0167814026006304"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111790","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic MRI-guided adaptive radiation therapy (SMART) for locally advanced pancreatic cancer: A prospective single-center cohort study","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111790"}}